{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T04:04:34Z","timestamp":1790827474036,"version":"4.1.0"},"reference-count":15,"publisher":"American Society for Microbiology","issue":"6","license":[{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2015,6]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            Ceftazidime-avibactam (MIC\n            <jats:sub>50\/90<\/jats:sub>\n            , 0.12\/0.25 \u03bcg\/ml) inhibited 99.9% (20,698\/20,709) of\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Enterobacteriaceae<\/jats:named-content>\n            isolates at \u22648 \u03bcg\/ml. This compound was active against resistant subsets, including ceftazidime-nonsusceptible\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Enterobacter cloacae<\/jats:named-content>\n            (MIC\n            <jats:sub>50\/90<\/jats:sub>\n            , 0.25\/0.5 \u03bcg\/ml) and extended-spectrum \u03b2-lactamase (ESBL) phenotype isolates. An ESBL phenotype was noted among 12.4% (1,696\/13,692 isolates from targeted species) of the isolates, including 776\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Escherichia coli<\/jats:named-content>\n            (12.0% for this species; MIC\n            <jats:sub>50\/90<\/jats:sub>\n            , 0.12\/0.25 \u03bcg\/ml), 721\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Klebsiella pneumoniae<\/jats:named-content>\n            (16.3%; MIC\n            <jats:sub>50\/90<\/jats:sub>\n            , 0.12\/0.25 \u03bcg\/ml), 119\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Klebsiella oxytoca<\/jats:named-content>\n            (10.3%; MIC\n            <jats:sub>50\/90<\/jats:sub>\n            , 0.06\/0.25 \u03bcg\/ml), and 80\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Proteus mirabilis<\/jats:named-content>\n            (4.9%; MIC\n            <jats:sub>50\/90<\/jats:sub>\n            , 0.06\/0.12 \u03bcg\/ml) isolates. The most common enzymes detected among ESBL phenotype isolates from 2013 (\n            <jats:italic>n<\/jats:italic>\n            = 743) screened using a microarray-based assay were CTX-M-15-like (\n            <jats:italic>n<\/jats:italic>\n            = 307), KPC (\n            <jats:italic>n<\/jats:italic>\n            = 120), SHV ESBLs (\n            <jats:italic>n<\/jats:italic>\n            = 118), and CTX-M-14-like (\n            <jats:italic>n<\/jats:italic>\n            = 110). KPC producers were highly resistant to comparators, and ceftazidime-avibactam (MIC\n            <jats:sub>50\/90<\/jats:sub>\n            , 0.5\/2 \u03bcg\/ml) and tigecycline (MIC\n            <jats:sub>50\/90<\/jats:sub>\n            , 0.5\/1 \u03bcg\/ml; 98.3% susceptible) were the most active agents against these strains. Meropenem (MIC\n            <jats:sub>50\/90<\/jats:sub>\n            , \u22640.06\/\u22640.06 \u03bcg\/ml) and ceftazidime-avibactam (MIC\n            <jats:sub>50\/90<\/jats:sub>\n            , 0.12\/0.25 \u03bcg\/ml) were active against CTX-M-producing isolates. Other enzymes were also observed, and ceftazidime-avibactam displayed good activity against the isolates producing less common enzymes. Among 11 isolates displaying ceftazidime-avibactam MIC values of &gt;8 \u03bcg\/ml, three were\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">K. pneumoniae<\/jats:named-content>\n            strains producing metallo-\u03b2-lactamases (all ceftazidime-avibactam MICs, &gt;32 \u03bcg\/ml), with two NDM-1 producers and one\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">K. pneumoniae<\/jats:named-content>\n            strain carrying the\n            <jats:italic>bla<\/jats:italic>\n            <jats:sub>KPC-2<\/jats:sub>\n            and\n            <jats:italic>bla<\/jats:italic>\n            <jats:sub>VIM-4<\/jats:sub>\n            genes. Therapeutic options for isolates producing \u03b2-lactamases may be limited, and ceftazidime-avibactam, which displayed good activity against strains, including those producing KPC enzymes, merits further study in infections where such organisms occur.\n          <\/jats:p>","DOI":"10.1128\/aac.00163-15","type":"journal-article","created":{"date-parts":[[2015,4,7]],"date-time":"2015-04-07T01:42:34Z","timestamp":1428370954000},"page":"3509-3517","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":111,"title":["Ceftazidime-Avibactam Activity Tested against Enterobacteriaceae Isolates from U.S. Hospitals (2011 to 2013) and Characterization of \u03b2-Lactamase-Producing Strains"],"prefix":"10.1128","volume":"59","author":[{"given":"Mariana","family":"Castanheira","sequence":"first","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet C.","family":"Mills","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah E.","family":"Costello","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald N.","family":"Jones","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helio S.","family":"Sader","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/1469-0691.12427"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1086\/668770"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkm318"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/nyas.12010"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-013-0013-7"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02252-12"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01896-13"},{"key":"e_1_3_2_9_2","volume-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard","author":"Clinical and Laboratory Standards Institute","year":"2012","unstructured":"Clinical and Laboratory Standards Institute. 2012. M07-A9. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 9th ed. Clinical and Laboratory Standards Institute, Wayne, PA.","edition":"9"},{"key":"e_1_3_2_10_2","volume-title":"Performance standards for antimicrobial susceptibility testing: 24th informational supplement","author":"Clinical and Laboratory Standards Institute","year":"2014","unstructured":"Clinical and Laboratory Standards Institute. 2014. M100-S24. Performance standards for antimicrobial susceptibility testing: 24th informational supplement. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_2_11_2","unstructured":"EUCAST. 2014. Breakpoint tables for interpretation of MICs and zone diameters. Version 4.0 January 2014. EUCAST Basel Switzerland. http:\/\/www.eucast.org\/clinical_breakpoints\/. Accessed January 2014."},{"key":"e_1_3_2_12_2","volume-title":"Ceftazidime-avibactam briefing package. NDA 206494","author":"Cerexa","year":"2014","unstructured":"Cerexa. 2014. Ceftazidime-avibactam briefing package. NDA 206494. Division of Anti-Infective Products, Office of Antimicrobial Products, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD. http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/Anti-InfectiveDrugsAdvisoryCommittee\/UCM425458.pdf. Accessed 8 January 2015."},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2013.03.032"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2012.05.021"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.2147\/CE.S40698"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.3947\/ic.2014.46.3.149"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00163-15","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00163-15","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T23:06:57Z","timestamp":1645484817000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.00163-15"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":15,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["10.1128\/AAC.00163-15"],"URL":"https:\/\/doi.org\/10.1128\/aac.00163-15","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6]]},"assertion":[{"value":"2015-01-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-03-30","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-05-14","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}